CYP2C19 and acute coronary syndrome: Of the two studies that evaluated Genomadix CYP2C19 test (version unclear), both were based in the Netherlands; one recruited acute coronary syndrome patients [52] and one recruited adult patients of participating community pharmacies who were taking P2Y12 inhibitor-based antiplatelet treatment with either ticagrelor/prasugrel, and who had not been CYP2C19 genotyped before [51].